Emodin derivatives as multi-target-directed ligands inhibiting monoamine oxidase and antagonizing vasopressin V1Areceptors

• Published in: ACS Omega
• Main Author: Paudel P.; Shrestha S.; Park S.E.; Seong S.H.; Fauzi F.M.; Jung H.A.; Choi J.S.
• Format: Article
• Language: English
• Published: American Chemical Society 2020
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85094199237&doi=10.1021%2facsomega.0c03649&partnerID=40&md5=ac8208adaa265c74f1b153436d05ffe0

The brain neurotransmitter level is associated with the pathology of various neurodegenerative diseases, and age-dependent increase in the blood level of vasopressin, human brain monoamine oxidase (hMAO) level, oxidative stress, and imbalance in aminergic signaling are common disease-modifying factors leading to various neurodegenerative disorders. Based on the reports of emodin in hMAO inhibition and antagonist effect on the vasopressin V1Areceptor, in this study we synthesized six emodin derivatives and evaluated their effects on MAO activity and G protein-coupled receptors. Among them, 4-hydroxyemodin and 5-hydroxyemodin were potent inhibitors of hMAO, and 2-hydroxyemodin and 5-hydroxyemodin were good V1AR antagonists. In silico molecular docking simulation revealed that the hydroxyl group at C2, C4, and C5 of the respective compounds interacted with prime residues, which corroborates the in vitro effect. Likewise, these three derivatives were predicted to have good drug-like properties. Overall, our study demonstrates that the hydroxyl derivatives of emodin are multi-target-directed ligands that may act as leads for the design and development of a therapy for central nervous system disorders. © 2020 American Chemical Society. All rights reserved.